Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Merck
McKinsey
Dow
AstraZeneca
Baxter

Last Updated: December 3, 2022

Details for Patent: 7,915,247


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which drugs does patent 7,915,247 protect, and when does it expire?

Patent 7,915,247 protects FIBRICOR and is included in one NDA.

Summary for Patent: 7,915,247
Title:Methods of use of fenofibric acid
Abstract:Fenofibric acid formulations comprising 105 mg of fenofibric acid are described as well as methods of use thereof. Dosage forms include, for example, immediate-release dosage forms.
Inventor(s): Arnold; Kristin Anne (Morrisville, PA), Feng; Hengsheng (Cherry Hill, NJ)
Assignee: Mutual Pharmaceutical Company, Inc. (Philadelphia, PA)
Application Number:12/141,280
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Drugs Protected by US Patent 7,915,247

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Athena FIBRICOR fenofibric acid TABLET;ORAL 022418-001 Aug 14, 2009 DISCN Yes No See Plans and Pricing See Plans and Pricing ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH MIXED DYSLIPIDEMIA See Plans and Pricing
Athena FIBRICOR fenofibric acid TABLET;ORAL 022418-001 Aug 14, 2009 DISCN Yes No See Plans and Pricing See Plans and Pricing ADJUNCTIVE THERAPY TO DIET TO PATIENTS WITH HYPERTRIGLYCERIDEMIA See Plans and Pricing
Athena FIBRICOR fenofibric acid TABLET;ORAL 022418-001 Aug 14, 2009 DISCN Yes No See Plans and Pricing See Plans and Pricing ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH HYPERLIPIDEMIAS See Plans and Pricing
Athena FIBRICOR fenofibric acid TABLET;ORAL 022418-002 Aug 14, 2009 RX Yes Yes See Plans and Pricing See Plans and Pricing ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH HYPERLIPIDEMIAS See Plans and Pricing
Athena FIBRICOR fenofibric acid TABLET;ORAL 022418-002 Aug 14, 2009 RX Yes Yes See Plans and Pricing See Plans and Pricing ADJUNCTIVE THERAPY TO DIET TO PATIENTS WITH HYPERTRIGLYCERIDEMIA See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Moodys
Mallinckrodt
Colorcon
Boehringer Ingelheim
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.